Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure

    Company Targeting to Complete Enrollment of 150 patients by March 2009

    SUNRISE, Fla., Sept. 30 /CNW/ -- Bioheart, Inc., (Nasdaq:   BHRT), today
announced that 35 of the leading U.S. Heart Failure Centers have engaged in
Bioheart's Phase II/III MARVEL(1) Trial of myogenic cells for treating
advanced heart failure.

    "With 35 leading heart failure centers engaged, we are making tremendous
progress in patient screening and enrollment," said Dr. Warren Sherman,
Principal Investigator and Director, Cardiac Cell-based Endovascular
Therapies, Columbia University Medical Center, New York.  "We have added
nearly 45 patients into our trial in the past three months."

    The MARVEL Trial, a randomized, double-blind, placebo-controlled,
multi-center Phase II/III Trial involving 330 patients in North America and
Europe, is the largest trial of its kind to date.  Enrollment in the MARVEL
Trial began in October 2007, targeting patients who fall into Class II or III
heart failure.  The MARVEL Trial is studying the safety and efficacy of
MyoCell autologous clinical cell therapy in the treatment of congestive heart
failure delivered via a MyoStar(TM) injection catheter(2), in combination with
the NOGA(R) XP Cardiac Navigation System.  The MyoCell injection process is a
minimally invasive procedure which presents less risk and considerably less
trauma to a patient than conventional (open) heart surgery.

    The trial is designed for an interim look at 150 patients with six-month
follow-up. Based on the statistical significance of these interim results, the
Company will explore the potential to submit for early commercial approval in
the United States.  Bioheart is on track to complete enrollment of 150
patients by March 2009, subject to its timely receipt of additional financing
and barring any unforeseen changes.

    This study has a cell concentration of up to 200 million cells/ml and
administers 16 injections per patient, with varying dosing per injection.
There are three study groups in the trial, one receiving a total of 800
million cells, one receiving a total of 400 million cells and the third
receiving placebo injections. In contrast, previous studies involving
MyoCell(R) Therapy had a cell concentration of 50 million cells/ml and
administered 32 injections per patient.  Animal studies involving MyoCell(R)
therapy have suggested increased cell retention, survival and engraftment with
the higher concentration of cells and lower number of injections, in part due
to lower inflammation response.

    "We expect the MARVEL Trial will confirm our current beliefs regarding
the safety and efficacy of MyoCell," said Howard J. Leonhardt, CEO and Chief
Technology Officer, Bioheart.  "Results from our completed Phase I US MYOHEART
Trial and Phase II European SEISMIC Trial showed 83-94 percent of the
MyoCell(R) treated heart failure patients improved, or did not worsen, in
Quality of Life or heart failure class while only 6-17 percent worsened.  In
comparison, in the SEISMIC Trial control group, 58 percent of the patients
that received drugs only improved or did not worsen while 42 percent of such
patients worsened.

    In October, Bioheart intends to apply for approval to market and
reimbursement for MYOCELL(R) Therapy in various countries in Europe for the
sickest Class III heart failure patients that continue to deteriorate despite
treatment with all currently available therapies applied including drugs,
pacers and mechanical assist devices, with no additional therapeutic options.

    Congestive heart failure (CHF), or heart failure, is a condition in which
the heart cannot pump enough oxygenated blood to the body's vital organs. 
People with heart failure find that they cannot exert themselves as they
become tired and short of breath.  Current therapeutic options include
palliative medical therapy (symptom-treating medicine), cardiac assist devices
or cardiac transplantation.  Heart failure is a leading cause of
hospitalizations in people over age 65.

    MyoCell(R) clinical cell therapy, developed by Bioheart, Inc., is
currently being studied as an investigational therapy in Europe and the U.S. 
MyoCell(R) clinical cell therapy is intended to be used to improve cardiac
function months or even years after a patient has suffered severe heart damage
due to a heart attack.  The procedure involves a physician removing a small
amount of muscle obtained from the patient's thigh.   From this muscle
specimen, autologous myoblasts (muscle stem cells) are then isolated, grown
using Bioheart's proprietary cell-culturing process, and injected directly
into the scar tissue of the patient's heart.  The myoblast cells are delivered
via an endoventricular needle-injection catheter during a minimally invasive
procedure performed by an interventional cardiologist or vascular surgeon. 
The myoblast-based muscle formation in the newly populated regions of scar
tissue are intended to improve cardiac function by helping the heart muscle
beat more efficiently.

    Bioheart, Inc. (Nasdaq:   BHRT) is committed to delivering intelligent
devices and biologics that help monitor, diagnose and treat heart failure and
cardiovascular diseases.  Its goals are to improve a patient's quality of life
and reduce health care costs and hospitalizations.  Specific to biotechnology,
Bioheart is focused on the discovery, development and, subject to regulatory
approval, commercialization of autologous cell therapies for the treatment of
chronic and acute heart damage.  Its lead product candidate, MyoCell(R), is an
innovative clinical muscle-derived stem cell therapy designed to populate
regions of scar tissue within a patient's heart with new living cells for the
purpose of improving cardiac function in chronic heart failure patients.  The
Company's pipeline includes multiple product candidates for the treatment of
heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose
tissue-derived stem cell treatment for acute heart damage, and MyoCell(R)
SDF-1, a therapy utilizing autologous cells that are genetically modified to
express additional potentially therapeutic growth proteins.  For more
information on Bioheart, visit

    (1) MARVEL: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled
Multi-center study to Assess the Safety and Cardiovascular Effects of MyoCell
Implantation by a Catheter Delivery System in Congestive Heart Failure
Patients Post-Myocardial Infarction(s)
    (2) The MYOSTAR(TM) Injection Catheter is not available for sale in the
U.S.  It is in use in IND investigations

    MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.
    MyoStar and NOGA XP are trademarks of Cordis Corporation, a Johnson &
Johnson company

    Forward Looking Statements:
    Except for historical matters contained herein, statements made in this
press release are forward-looking and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.  Without
limiting the generality of the foregoing, words such as "may", "will", "to",
"plan", "expect",
    "believe", "anticipate", "intend", "could", "would", "estimate", or
"continue" or the negative other variations thereof or comparable terminology
are intended to identify forward-looking statements.

    Investors and others are cautioned that a variety of factors, including
certain risks, may affect our business and cause actual results to differ
materially from those set forth in the forward-looking statements.  These risk
factors include, without limitation, (i) our ability to secure additional
financing; (ii) the timely success and completion of our clinical trials;
(iii) the occurrence of any unacceptable side effects during or after
preclinical and clinical testing of our product candidates; (iv) regulatory
approval of our product candidates; (v) our dependence on the success of our
lead product candidate; (vi) our inability to predict the extent of our future
losses or if or when we will become profitable; (vii) our ability to protect
our intellectual property rights; (viii) our inability to predict the extent
of our future losses or if or when we will become profitable; and (viii)
intense competition . The company is also subject to the risks and
uncertainties described in its filings with the Securities and Exchange
Commission, including the section titled "Risk Factors" in its Annual Report
on Form 10-K for the year ended December 31, 2007, as amended by Amendment No.
1 on Form 10-K/A and its quarterly report on Form 10-Q for the quarters ended
March 31, 2008 and June 30, 2008.


For further information:

For further information: Marty Schildhouse, +1-305-606-3577, or Robert
Murphy, +1-908-276-0777, both of The Storch-Murphy Group Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890